Biotech Winter, Not Ice Age: The Bull Case for Alexandria at a Fire Sale

irreplaceable assets trade at 40% of "replacement cost"

Thesis Highlight

If Life Science REITs held an Olympics, Alexandria would be the 1992 U.S. Dream Team: Jordan, Magic Johnson, and Bird all on one roster.

Yet today, this elite franchise trades 75% off its 2022 all-time high, caught in a brutal “Biotech Winter.” At $45 per share, the market prices in permanent damage.

We see something else: irreplaceable class A life science campuses (blocks next to MIT, UCSF, and UCSD) trading at ~40% of replacement cost, with 55-140% upside to conservative normalized valuation.

We stress-test two biggest bear fears (forever biotech winter and value-destructive management), walk through the crown-jewel assets, and reveal a powerful bonus most investors miss.

Welcome to the Dream Team of life science REITs - Alexandria.

The Story

Alexandria ARE 0.00%↑ owns 36Mn Rentable SqFt (RSF) across 339 life science properties in top innovation hubs (Boston, San Francisco, and San Diego).

The portfolio features high-spec buildings in prime locations with strong-credit tenants, delivering high 90% occupancy and steady rent growth for years.

However, since 2023, the life science sector has faced headwinds from policy uncertainty, funding constraints, and oversupply. As a result, ARE has seen higher vacancy, softer leasing, and rents increasing below inflation, with current Annual Rental Revenue (ARR) at ~$1.9 billion. The table below illustrates the trend.

The stock reflects this pain: down ~63% since Jan 2020 and ~75% from its Jan 2022 ATH. Today it trades at ~$45/share ($8Bn market cap, $20Bn EV). At its peak in Jan 22, it had a $40 Bn market cap and a $50 Bn EV.

3 Headwinds arriving at Once

The market verdict is harsh, but not without cause.

Three forces hit simultaneously: a biotech funding winter, a hostile policy environment, and a self-inflicted overbuilding hangover.

Let us take a look.

Headwind 1 - The Biotech Funding Winter: Dedicated biotech VC funds collapsed from $30.8B in 2021 to $11.7B in 2024: fewer funds, fewer startups, fewer leases. ARE’s occupancy fell from 95% in 2022 to 87.7% by Q1 2026.

Two mitigants. First, 53% of ARE’s revenue comes from large pharma anchors: Biogen, Novartis, AstraZeneca, unaffected by the VC cycle. Second, early-stage biotech is thawing: VC deal value jumped 70.9% from Q2 to Q3 2025. But funding recovery lags lease signings by 18–36 months. The floor is forming, but the full recovery takes time.

Headwind 2 - Government Policy: In its leaked FY26 budget proposal, the Trump administration proposed cutting NIH’s $48B budget by 44%, to $26.7B, a threat to the biotech startup ecosystem that fills ARE’s building.

It did not happen. In Jan ‘26, the Congress passed the bill that rejected the proposed cuts and increased NIH's base budget to $48.7B, a $415M increase over 2025.

Researchers were rattled by freezes and cancellations of already-awarded grants and long delays in new awards, despite Congress having appropriated the funds. A startup waiting on a frozen grant cannot sign a lease in the meantime. The headline risk is gone, but the hangover takes time to clear.

Headwind 3 - self-inflicted overbuilding: During the Y20–21 euphoria, ARE grew its development pipeline to over 5.6 million RSF. It was not alone; developers across key markets broke ground in lockstep. Lab space supply grew 7.5x since 2021 even as demand dropped approximately 60% from its peak. Boston-wide lab vacancy hit 30% by late 2025.

ARE was paying over $ 200 M in annual interest on $4.2B in pre- and under-construction assets producing zero NOI.

ARE took $2.2B impairment charges in 2025. The damage is done. The question now is whether its strategic reset, outlined at Investor Day 2025, is real and durable. We will discuss the execution scorecard in a later section.

A Compelling Valuation

At $45/share, ARE trades at a compelling discount:

• Cap rate: Using 7% and 5.5% cap rates value the stock at $70 and $109 per share.

• Replacement cost: Even at 50% of rebuild cost, it would imply $85 per share.

While both estimates present meaningful upside potential (55% - 140%), they remain conservative, AND exclude:

• 3Mn RSF development pipeline ($2Bn invested and ~2/3 complete)

• ~$1Bn venture portfolio at cost ($1.5Bn carrying value)

At 3Bn cost, that equates to ~$20/share.

The Crown Jewel Assets

Alexandria’s real edge is unmatched location and quality. Its flagship campuses sit directly adjacent to America’s top research institutions.

Kendall Square @ MIT/Cambridge: The most innovative square mile on earth. Alexandria dominates with a 5.4M RSF Campus. While Greater Boston vacancy hit 30%, Kendall Square has held up significantly better and commands premium rents.

Mission Bay @ UCSF/San Francisco: Prime assets next to UCSF. These trade in a clearly stronger tier than the weak broader market. Recent sales to UCSF at $1,650/sqft highlight the demand.

University Town Center @ UCSD/San Diego: ARE dominates this submarket with 99% occupancy (mid-2025), way above San Diego’s 30% vacancy, backed by long-term deals with top tenants.

There is only one MIT, one UCSF, and one UCSD. The ecosystem advantage is paramount.

The Bear Cases

Two main concerns dominate the narrative:

1. Biotech’s Forever Winter: Will prolonged funding pressure, policy risk, and oversupply drive occupancy and rents materially lower, eventually threatening the balance sheet?

2. Value-Destructive Management: Aggressive expansion during the boom years led to rising leverage and a 45% dividend cut. Will / can management turn around?

Behind the paywall, we will walk through Alexandria’s key assets, discuss the valuation math, address both bear cases, highlight its downside protection, our position plan, and more.